BSD Medical is Now Pyrexar Medical

The link between increased longevity and hyperthermia treatment was considered a landmark study when it published in late 2018 in the Journal of the American Medical Association.

Recently, our partners at Sennewald Medizintechnik, caught up with renowned expert and cancer study co-author Professor Dr. Lars Lindner of Ludwig-Maximilians-Universität (LMU) in Munich to get a deeper understanding of the findings.

After examining over 30 Soft Tissue Sarcoma trials, Prof. Dr. Linder lists the top four significant findings:

1. Doxorubicin-based chemotherapy is and remains the standard of care for soft tissue sarcomas.
2. The benefit of chemotherapy has also been shown in the adjuvant situation in high-risk patients.
3. Neoadjuvant therapy is preferable because it combats potential micrometastasis at the earliest possible time and improves operability.
4. Regional hyperthermia improves the effectiveness of chemotherapy and leads to improved patient survival.

The complete interview is available on the Sennewald Medizintechnik April 2021 newsletter.

The 2020 ESHO-Pyrexar Award presentation included the history and merits of Professor Niloy Datta, celebrating his achievements in the field of thermal oncology.  What follows the award presentation is nothing less than a Master Class in thermal oncology.  Dr. Datta shares highlights of his research and his vision for the pathway to hyperthermia expansion and success.

Along with presenting evidence of the increased value to the patient that hyperthermia brings, Dr. Datta also touches on the financial rationale of adding a thermal oncology program to your hospital.

Below find a summary of recently published works involving hyperthermia by Datta et al.

 A special thanks to Dr. Sennewald Medizintechnik for sponsoring the award and presentation.

Medical news may be dominated by pandemic coverage, but cancer research still moves forward.  We did a quick search on clinicaltrials.gov for trials using hyperthermia as an adjunct to radiotherapy, chemotherapy, and immunotherapy.  The listing below is a summary of studies around the world. 

HIPEC studies have not been included in this list. Listing facilities with Pyrexar hyperthermia systems is not a statement that those systems are used in the study, only that they exist at the facilities conducting the study.  If you know of a study not included in the list, please let us know, and we would be happy to share it on our website.

Ivy-Lab Inc., established in 2008, specializes in the supply of medical devices in South Korea. The sales group has been very successful in placing the BSD-2000 Deep Regional Hyperthermia system in hospitals all over the country.

According to CEO  Michael Cha, "is to make the best cancer care available to everyone. We believe the radiative method of hyperthermia is the most efficient hyperthermia method in fighting cancer as it has been proven many times over. That is why we aim to spread the word of radiative hyperthermia to all South Korean doctors and specialists and create awareness in the country".

Ivy Lab has been extremely successful in the very competitive South Korean market; this position elevation as a master distributor ensures that we will continue to see dynamic growth in the region.